解剖型全肩关节置换术长期成功的定义:生存率与临床重要结局
该回顾性队列研究纳入2003至2015年间791例连续解剖型全肩关节置换术,采用Kaplan-Meier分析假体生存率,并以患者满意度为锚定推导ASES评分的临床重要阈值。结果显示10年生存率96.1%、15年93.7%,10年时69.5%肩关节达到PASS阈值68.1,55.8%达到SCB阈值39.2。
要点
- aTSA十年假体生存率96.1%,十五年93.7%。
- 十年时69.5%肩关节达到ASES的PASS阈值68.1。
- 年轻年龄和Walch B型肩胛盂形态独立增加翻修风险。
核心结论
- aTSA具有优异的长期假体生存率,患者报告结局虽随时间逐渐衰减但多数在10年时仍维持临床有意义的获益。
- 年轻年龄和Walch B型肩胛盂形态与翻修风险增加独立相关。
- 长期临床重要阈值可为定义持久成功提供以患者为中心的基准。
研究设计与样本
- 回顾性队列研究,纳入2003至2015年间791例连续解剖型全肩关节置换术。
- 采用Kaplan-Meier分析评估假体生存率,以患者满意度为锚定推导ASES评分的临床重要阈值。
- 采用多变量回归识别翻修和实质性临床获益(SCB)的预测因素。
- 证据等级:预后Level III。
主要发现
- Kaplan-Meier生存率10年为96.1%,15年为93.7%。
- Walch B型肩胛盂形态和年轻年龄与翻修独立相关。
- 长期随访临床结局虽逐渐衰减但仍改善。
- 10年时69.5%肩关节达到PASS阈值68.1。
- ASES评分变化的MCID和SCB阈值分别为14.0和39.2,分别有79.9%和55.8%肩关节达到。
关键数值与推荐
- 10年时ASES评分PASS阈值为68.1,69.5%肩关节达到。
- ASES评分变化的MCID阈值为14.0,79.9%肩关节达到。
- ASES评分变化的SCB阈值为39.2,55.8%肩关节达到。
- 年轻年龄、原发性盂肱骨关节炎和较低术前ASES评分与达到SCB独立相关。
临床怎么用
- 临床可参考aTSA长期生存率和ASES的PASS、MCID、SCB阈值评估患者获益。
- 对年轻患者和Walch B型肩胛盂形态患者应关注翻修风险。
- 长期随访中尽管功能逐渐衰减,仍应关注患者是否维持临床有意义的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term success after anatomic total shoulder arthroplasty (aTSA) is frequently defined by implant survivorship, but revision-free survival may not reflect durable clinical benefit. METHODS: A retrospective cohort study of 791 consecutive aTSAs performed between 2003 and 2015 was conducted. Implant survivorship was assessed using Kaplan-Meier analysis. Clinical outcomes were evaluated at a 10-year landmark, and clinically important thresholds for the American Shoulder and Elbow Surgeons (ASES) score were derived using patient satisfaction as the anchor. Multivariable regression identified predictors of revision and substantial clinical benefit (SCB). RESULTS: Kaplan-Meier survivorship was 96.1% at 10 years and 93.7% at 15 years. Walch B glenoid morphology and younger age were independently associated with revision. Clinical outcomes remained improved at long-term follow-up despite gradual attenuation over time. At 10 years, the patient acceptable symptom state (PASS) threshold for the ASES score was 68.1, and 69.5% of shoulders achieved it. The minimal clinically important difference (MCID) and SCB thresholds for the change in ASES score were 14.0 and 39.2, achieved by 79.9% and 55.8% of shoulders, respectively. Younger age, primary glenohumeral osteoarthritis, and lower preoperative ASES score were independently associated with achievement of SCB. CONCLUSIONS: aTSA demonstrated excellent long-term implant survivorship and modest patient-reported outcomes, although shoulder function gradually attenuated over extended follow-up. Despite the gradual functional decline, most patients maintained clinically meaningful benefit at 10 years. Younger age and Walch B morphology increased revision risk. Long-term clinically important thresholds provide patient-centered benchmarks for defining durable success. LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Kucharik MP, Hung V, Jones T, et al. Defining Long-Term Success After Anatomic Total Shoulder Arthroplasty: Survivorship and Clinically Important Outcomes. J Bone Joint Surg Am. 2026. PMID: 42853908. doi:10.2106/JBJS.26.00452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。